Known targets — ChEMBL curated mechanism
DHFRGARTPTGFRPTGIRPTGS1PTGS2TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8envmurAthyA
The experimentally established mechanism targets of Tromethamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tromethamine SCHEMBL2944900 | 0.89 | MEN1 (0.71) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL14735910 | 0.88 | MEN1 (0.83) | MEN1LMNAKMT2AKDM4EPOLB | |
| Tromethamine SCHEMBL17484 | 0.88 | MEN1 (1.00) | MEN1LMNAKMT2AKDM4EPOLB | |
| Tromethamine SCHEMBL975 | 0.88 | — | — | |
| Tromethamine SCHEMBL3696191 | 0.88 | — | — | |
| Tromethamine SCHEMBL10528593 | 0.86 | MEN1 (0.67) | MEN1LMNAKMT2A | |
| Tromethamine SCHEMBL7091147 | 0.84 | — | — | |
| Tromethamine SCHEMBL6427079 | 0.84 | — | — | |
| Tromethamine SCHEMBL445853 | 0.84 | MEN1 (0.91) | MEN1LMNAKMT2AKDM4EPOLB | |
| Tromethamine SCHEMBL9298764 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927067-B2 | Organic crystalline salt of haloacetic acid | PARAYIL SARIN (IN) | 2021-02-23 | — | — | US | disclosed |
| US-20200039919-A1 | NOVEL ORGANIC CRYSTALLINE SALT OF HALOACETIC ACID | PARAYIL SARIN (IN) | 2020-02-06 | — | — | US | disclosed |
| WO-2018096517-A1 | NOVEL ORGANIC CRYSTALLINE SALT OF HALOACETIC ACID | PARAYIL SARIN (IN) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927067-B2 | Organic crystalline salt of haloacetic acid | SLC6A6, SLC10A6, REN | MEN1 3353/4885LMNA 4101/4885KMT2A 835/4885 |
| US-20200039919-A1 | NOVEL ORGANIC CRYSTALLINE SALT OF HALOACETIC ACID | SLC6A6, SLC10A6, REN | MEN1 3257/4885LMNA 4269/4885KMT2A 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.